Raw Ground Truth
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.comInclusion Criteria:Newly Diagnosed Acute Myeloid Leukemia (AML)Considered inappropriate for intensive remission induction therapy by an investigatorNot eligible for stem cell transplantationExclusion Criteria:Acute promyelocytic leukemiaCurrent Myelodysplastic syndrome only subjectsOther protocol defined inclusion/exclusion criteria could apply
Raw Prediction
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- AML
- Considered inappropriate for intensive remission induction therapy by an investigator
- Not eligible for stem cell transplantation
Exclusion Criteria:
- Acute promyelocytic leukemia
- Myelodysplastic syndrome only subjects
Note: The exclusion criteria was revised to specify allogeneic transplants in patients who received prior hematopoietic stem cell transplantation.
Processed Ground Truth
1. For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.comInclusion Criteria:Newly Diagnosed Acute Myeloid Leukemia (AML)Considered inappropriate for intensive remission induction therapy by an investigatorNot eligible for stem cell transplantationExclusion Criteria:Acute promyelocytic leukemiaCurrent Myelodysplastic syndrome only subjectsOther protocol defined inclusion/exclusion criteria could apply
Processed Prediction
1. For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
1. AML
2. Considered inappropriate for intensive remission induction therapy by an investigator
3. Not eligible for stem cell transplantation
1. Acute promyelocytic leukemia
2. Myelodysplastic syndrome only subjects
3. Note: The exclusion criteria was revised to specify allogeneic transplants in patients who received prior hematopoietic stem cell transplantation.